Evaluation of Bone Turnover Markers in Patients with Acute and Chronic Leukemia

Overview

Journal Indian J Clin Biochem

Specialty Biochemistry

Date 2024 Jul 15

PMID 39005859

Authors

Reem A Al-Qaisi

Abdulnasser M Al-Gebori

Mohammed Hadi Munshed Alosami

Affiliations

Soon will be listed here.

Abstract

This study investigated different bone biomarkers (cross-linked carboxy-terminal telopeptide of type 1 collagen (CTX-1), pyridinoline (PYD), osteocalcin (OC), interleukin-6 receptor (IL-6R), calcium (Ca), and magnesium (Mg)) in terms of their metabolism in 4 different leukemia subtypes (ALL, AML, CLL and CML). The design was case control study with 30 controls and 60 cases of leukemia patients. Authors have reported many results regarding decrease as well as increase of specific bone biomarker under investigation with each leukemia subtype when compared to control. In addition, Authors reported correlations between each biomarker level and leukemia subtypes.

References

Rasool M, Farooq S, Malik A, Shaukat A, Manan A, Asif M . Assessment of circulating biochemical markers and antioxidative status in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients. Saudi J Biol Sci. 2015; 22(1):106-11. PMC: 4281600. DOI: 10.1016/j.sjbs.2014.09.002. View

Nakchbandi I, Mitnick M, Lang R, Gundberg C, Kinder B, Insogna K . Circulating levels of interleukin-6 soluble receptor predict rates of bone loss in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2002; 87(11):4946-51. DOI: 10.1210/jc.2001-011814. View

Frisch B, Ashton J, Xing L, Becker M, Jordan C, Calvi L . Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia. Blood. 2011; 119(2):540-50. PMC: 3384480. DOI: 10.1182/blood-2011-04-348151. View

Pievani A, Donsante S, Tomasoni C, Corsi A, Dazzi F, Biondi A . Acute myeloid leukemia shapes the bone marrow stromal niche . Haematologica. 2020; 106(3):865-870. PMC: 7928008. DOI: 10.3324/haematol.2020.247205. View

Kim J, Lin C, Stavre Z, Greenblatt M, Shim J . Osteoblast-Osteoclast Communication and Bone Homeostasis. Cells. 2020; 9(9). PMC: 7564526. DOI: 10.3390/cells9092073. View

Kuo T, Chen C . Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomark Res. 2017; 5:18. PMC: 5436437. DOI: 10.1186/s40364-017-0097-4. View

Chen Y, Hoffmeister L, Zaun Y, Arnold L, Schmid K, Giebel B . Acute myeloid leukemia-induced remodeling of the human bone marrow niche predicts clinical outcome. Blood Adv. 2020; 4(20):5257-5268. PMC: 7594397. DOI: 10.1182/bloodadvances.2020001808. View

Malinowska J, Malecka M, Ciepiela O . Variations in Magnesium Concentration Are Associated with Increased Mortality: Study in an Unselected Population of Hospitalized Patients. Nutrients. 2020; 12(6). PMC: 7353204. DOI: 10.3390/nu12061836. View

Ciarcia R, Vitiello M, Galdiero M, Pacilio C, Iovane V, dAngelo D . Imatinib treatment inhibit IL-6, IL-8, NF-KB and AP-1 production and modulate intracellular calcium in CML patients. J Cell Physiol. 2011; 227(6):2798-803. DOI: 10.1002/jcp.23029. View

10.

Borge M, Delpino M, Podaza E, Stanganelli C, Palau-Nagore V, Roisman A . Soluble RANKL production by leukemic cells in a case of chronic lymphocytic leukemia with bone destruction. Leuk Lymphoma. 2016; 57(10):2468-71. DOI: 10.3109/10428194.2016.1151506. View

11.

Gupta A, Moore J . Tumor Lysis Syndrome. JAMA Oncol. 2018; 4(6):895. DOI: 10.1001/jamaoncol.2018.0613. View

12.

Krevvata M, Silva B, Manavalan J, Galan-Diez M, Kode A, Matthews B . Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts. Blood. 2014; 124(18):2834-46. PMC: 4314530. DOI: 10.1182/blood-2013-07-517219. View

13.

Tibullo D, Giallongo C, La Cava P, Berretta S, Stagno F, Chiarenza A . Effects of imatinib mesylate in osteoblastogenesis. Exp Hematol. 2009; 37(4):461-8. DOI: 10.1016/j.exphem.2008.12.008. View

14.

Berman E, Girotra M, Cheng C, Chanel S, Maki R, Shelat M . Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. Leuk Res. 2013; 37(7):790-4. DOI: 10.1016/j.leukres.2013.02.005. View

15.

Jaeger B, Tauer J, Ulmer A, Kuhlisch E, Roth H, Suttorp M . Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment. Med Sci Monit. 2012; 18(12):CR721-8. PMC: 3560809. DOI: 10.12659/msm.883599. View

16.

PAUNIER L . Effect of magnesium on phosphorus and calcium metabolism. Monatsschr Kinderheilkd. 1992; 140(9 Suppl 1):S17-20. View

17.

Ahn M, Suh B . Bone morbidity in pediatric acute lymphoblastic leukemia. Ann Pediatr Endocrinol Metab. 2020; 25(1):1-9. PMC: 7136509. DOI: 10.6065/apem.2020.25.1.1. View

18.

Reeh H, Rudolph N, Billing U, Christen H, Streif S, Bullinger E . Response to IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor α to gp130 expression: fusing experimental insights and dynamic modelling. Cell Commun Signal. 2019; 17(1):46. PMC: 6525395. DOI: 10.1186/s12964-019-0356-0. View

19.

OSullivan S, Horne A, Wattie D, Porteous F, Callon K, Gamble G . Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab. 2009; 94(4):1131-6. DOI: 10.1210/jc.2008-2324. View

20.

Tauer J, Hofbauer L, Jung R, Gerdes S, Glauche I, Erben R . Impact of long-term exposure to the tyrosine kinase inhibitor imatinib on the skeleton of growing rats. PLoS One. 2015; 10(6):e0131192. PMC: 4479438. DOI: 10.1371/journal.pone.0131192. View